These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 10277339)

  • 1. Monopolies, Maricopa, and marketing: a case study.
    Perkins J; Mercer A; McClary C
    Hosp Health Serv Adm; 1986; 31(4):34-44. PubMed ID: 10277339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of preferred provider organizations and its antitrust implications.
    Maram BS
    J Med Pract Manage; 1985 Oct; 1(2):130-5. PubMed ID: 10281825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are PPOs a competitive force or antitrust risk?
    Enders RJ
    Healthc Financ Manage; 1986 May; 40(5):52-60. PubMed ID: 10276171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can provider antitrust suits against payers be successful?
    Enders RJ
    Healthc Financ Manage; 1986 Jun; 40(6):72-80. PubMed ID: 10276682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives. PPOs face antitrust problems.
    Wash Rep Med Health; 1984 Nov; 38(44):suppl 4p. PubMed ID: 10268861
    [No Abstract]   [Full Text] [Related]  

  • 6. Court: Indiana Blues may adopt PPO plan without antitrust scrutiny.
    Allen HS; Rothschild IS
    Health Law Vigil; 1986 Apr; 9(8):4-5. PubMed ID: 10278389
    [No Abstract]   [Full Text] [Related]  

  • 7. The FTC and provider-controlled PPO price negotiations.
    Miles JJ
    Health Law Vigil; 1988 Jan; 11(3):6-10. PubMed ID: 10285716
    [No Abstract]   [Full Text] [Related]  

  • 8. Proposed FTC consent order first to prohibit PPO price-fixing and concerted negotiations.
    Miles JJ
    Health Law Vigil; 1988 Jan; 11(2):9-10, 14. PubMed ID: 10285312
    [No Abstract]   [Full Text] [Related]  

  • 9. Preferred provider organizations and antitrust policy: some recent issues.
    Costillo LB
    Health Matrix; 1986; 4(2):22-5. PubMed ID: 10278618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitrust and the new competition in health care: excerpts.
    Ginsburg DH
    Med Prod Sales; 1986 Apr; 17(4):39-42. PubMed ID: 10276459
    [No Abstract]   [Full Text] [Related]  

  • 11. Understanding antitrust: focus on the relevant market.
    Enders RJ
    Healthc Financ Manage; 1986 Feb; 40(2):25-32. PubMed ID: 10275004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPOs facing potential antitrust worries.
    Tarnoff S
    Bus Insur; 1985 Jul; 19(29):16, 20. PubMed ID: 10271746
    [No Abstract]   [Full Text] [Related]  

  • 13. Federal antitrust agencies send mixed signals to PPOs.
    Enders RJ
    Health Care Law Newsl; 1986 Jul; 1(1):12-4. PubMed ID: 10277502
    [No Abstract]   [Full Text] [Related]  

  • 14. Alternative delivery systems are focus of antitrust scrutiny.
    Scammon DL; Fuller DA; Sheffet MJ
    J Health Care Mark; 1987 Jun; 7(2):77-81. PubMed ID: 10282715
    [No Abstract]   [Full Text] [Related]  

  • 15. Planning PPOs to minimize antitrust risk.
    Clanton DA
    Hospitals; 1985 Mar; 59(5):96, 98. PubMed ID: 3972373
    [No Abstract]   [Full Text] [Related]  

  • 16. FTC letter further confuses PPO price-fixing issue.
    Miles JJ
    Health Law Vigil; 1986 May; 9(9):5-7. PubMed ID: 10276714
    [No Abstract]   [Full Text] [Related]  

  • 17. Preferred provider organizations: an antitrust warning.
    Sandler AL
    Group Pract J; 1987; 36(6):41-2, 44. PubMed ID: 10284861
    [No Abstract]   [Full Text] [Related]  

  • 18. Operational and legal implications of preferred provider organizations.
    Adams-Ryan D; Peddecord KM; Root GL
    Hosp Health Serv Adm; 1985; 30(3):44-57. PubMed ID: 10271468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provider-sponsored ADSs: reducing antitrust liability after Maricopa.
    Walsh JH; Feller H
    Spec Law Dig Health Care (Mon); 1985 Apr; 7(2):5-25. PubMed ID: 10270877
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacy participation in PPOs: an antitrust review.
    Health Matrix; 1984-1985 Winter; 2(4):35-7. PubMed ID: 10272758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.